AstraZeneca receives $1.2bn to scale-up and deliver Oxford’s COVID-19 vaccine, antibody testing gains momentum as a deal is struck between Roche and the NHS and details start to emerge on the future of the UK’s relationship with the EU.
Pharmaceutical, healthcare and biotech companies are at the forefront of the COVID-19 response, from therapeutic drug trials and vaccine development to the production of personal protective equipment (PPE) and ventilators.
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This kit is for research use only and launched under the T-SPOT Discovery brand. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner.
A new support fund for innovative firms struggling to access equity finance during the COVID-19 disruption has opened for applications today (20 May). The Future Fund, run by the British Business Bank, will provide convertible loans of between £125,000 and £5m to businesses if they can also secure matched funding from third-party investors.
Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, announced that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.